Bis-(hydroxyalkylamino)-anthraquinone inhibitors of protein kinase C
US5204370A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Nov 5, 1990 |
| Grant date | Apr 20, 1993 |
| Priority date | — |
| Expiry date | Nov 5, 2010 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D303/36
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention provides novel substituted anthraquinones having the formula ##STR1## wherein R.sub.1 and R.sub.2 are independently H, C.sub.1 -C.sub.10 alkyl, aryl, arylalkyl, alkylaryl; PA1 n and m are independently 1, 2, or 3; PA1 A is Halogen, OH, alkoxy, OCO(NR.sub.3 R.sub.4), S--C(NH.sub.2).dbd.NR.sub.5, or when m=1, comprises an oxirane ring with the adjacent oxygen atom; PA1 R.sub.3, R.sub.4, and R.sub.5 are independently H, alkyl, or aryl; PA1 X is H, OH, NR.sub.6 R.sub.7, Cl, Br, I, F, alkyl, aryl, alkoxy, aryloxy, COOR.sub.8, or CONR.sub.9 R.sub.10 ; and PA1 R.sub.6, R.sub.7, R.sub.8, R.sub.9, and R.sub.10 are independently H, lower alkyl, or aryl useful for inhibiting protein kinase C and treating conditions related to, or affected by inhibition of protein kinase C, particularly cancer tumors, inflammatory disease, reperfusion injury, and cardiac dysfunctions related to reperfusion injury.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.